271 related articles for article (PubMed ID: 35487282)
21. Biomaterials-assisted construction of neoantigen vaccines for personalized cancer immunotherapy.
Wu Y; Feng L
Expert Opin Drug Deliv; 2023 Mar; 20(3):323-333. PubMed ID: 36634017
[TBL] [Abstract][Full Text] [Related]
22. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
Aldous AR; Dong JZ
Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
[TBL] [Abstract][Full Text] [Related]
23. Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report.
Zeng Y; Zhang W; Li Z; Zheng Y; Wang Y; Chen G; Qiu L; Ke K; Su X; Cai Z; Liu J; Liu X
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439798
[TBL] [Abstract][Full Text] [Related]
24. Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
Morisaki T; Hikichi T; Onishi H; Morisaki T; Kubo M; Hirano T; Yoshimura S; Kiyotani K; Nakamura Y
Immunol Invest; 2021 Jul; 50(5):562-579. PubMed ID: 32660279
[TBL] [Abstract][Full Text] [Related]
25. Methods behind neoantigen prediction for personalized anticancer vaccines.
Godazandeh K; Van Olmen L; Van Oudenhove L; Lefever S; Bogaert C; Fant B
Methods Cell Biol; 2024; 183():161-186. PubMed ID: 38548411
[TBL] [Abstract][Full Text] [Related]
26. Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC).
Chen H; Yang G; Xiao J; Zheng L; You L; Zhang T
Cancer Lett; 2020 Oct; 490():12-19. PubMed ID: 32590021
[TBL] [Abstract][Full Text] [Related]
27. Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy.
Dunn GP; Cloughesy TF; Maus MV; Prins RM; Reardon DA; Sonabend AM
Neuro Oncol; 2020 Oct; 22(10):1425-1438. PubMed ID: 32615600
[TBL] [Abstract][Full Text] [Related]
28. Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma.
Mørk SK; Kadivar M; Bol KF; Draghi A; Westergaard MCW; Skadborg SK; Overgaard N; Sørensen AB; Rasmussen IS; Andreasen LV; Yde CW; Trolle T; Garde C; Friis-Nielsen J; Nørgaard N; Christensen D; Kringelum JV; Donia M; Hadrup SR; Svane IM
Oncoimmunology; 2022; 11(1):2023255. PubMed ID: 35036074
[TBL] [Abstract][Full Text] [Related]
29. Synthetic High-density Lipoprotein Nanodiscs for Personalized Immunotherapy Against Gliomas.
Scheetz L; Kadiyala P; Sun X; Son S; Hassani Najafabadi A; Aikins M; Lowenstein PR; Schwendeman A; Castro MG; Moon JJ
Clin Cancer Res; 2020 Aug; 26(16):4369-4380. PubMed ID: 32439701
[TBL] [Abstract][Full Text] [Related]
30. Neoantigens in precision cancer immunotherapy: from identification to clinical applications.
Zhang Q; Jia Q; Zhang J; Zhu B
Chin Med J (Engl); 2022 Jun; 135(11):1285-1298. PubMed ID: 35838545
[TBL] [Abstract][Full Text] [Related]
31. Challenges in developing personalized neoantigen cancer vaccines.
Katsikis PD; Ishii KJ; Schliehe C
Nat Rev Immunol; 2024 Mar; 24(3):213-227. PubMed ID: 37783860
[TBL] [Abstract][Full Text] [Related]
32. Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?
Wirth TC; Kühnel F
Front Immunol; 2017; 8():1848. PubMed ID: 29312332
[TBL] [Abstract][Full Text] [Related]
33. Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion.
Cai Z; Su X; Qiu L; Li Z; Li X; Dong X; Wei F; Zhou Y; Luo L; Chen G; Chen H; Wang Y; Zeng Y; Liu X
Mol Cancer; 2021 Dec; 20(1):164. PubMed ID: 34903219
[TBL] [Abstract][Full Text] [Related]
34. Neoantigens and NK Cells: "Trick or Treat" the Cancers?
Lv D; Khawar MB; Liang Z; Gao Y; Sun H
Front Immunol; 2022; 13():931862. PubMed ID: 35874694
[TBL] [Abstract][Full Text] [Related]
35. Colorectal cancer vaccines: Tumor-associated antigens
Wagner S; Mullins CS; Linnebacher M
World J Gastroenterol; 2018 Dec; 24(48):5418-5432. PubMed ID: 30622371
[TBL] [Abstract][Full Text] [Related]
36. Targeting Tumor Heterogeneity with Neoantigen-Based Cancer Vaccines.
Pounraj S; Chen S; Ma L; Mazzieri R; Dolcetti R; Rehm BHA
Cancer Res; 2024 Feb; 84(3):353-363. PubMed ID: 38055891
[TBL] [Abstract][Full Text] [Related]
37. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives.
Chen X; Yang J; Wang L; Liu B
Theranostics; 2020; 10(13):6011-6023. PubMed ID: 32483434
[TBL] [Abstract][Full Text] [Related]
38. Harnessing tumor immunogenomics: Tumor neoantigens in ovarian cancer and beyond.
Wu M; Zhou S
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):189017. PubMed ID: 37935309
[TBL] [Abstract][Full Text] [Related]
39. Dendritic cell vaccine trials in gliomas: Untangling the lines.
Hotchkiss KM; Batich KA; Mohan A; Rahman R; Piantadosi S; Khasraw M
Neuro Oncol; 2023 Oct; 25(10):1752-1762. PubMed ID: 37289203
[TBL] [Abstract][Full Text] [Related]
40. Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy.
Okada M; Shimizu K; Fujii SI
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
